GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pacira BioSciences Inc (NAS:PCRX) » Definitions » Owner Earnings per Share (TTM)

PCRX (Pacira BioSciences) Owner Earnings per Share (TTM) : -0.91 (As of Dec. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Pacira BioSciences Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Pacira BioSciences's Owner Earnings per Share (TTM) ended in Dec. 2024 was $-0.91. It's Price-to-Owner-Earnings ratio for today is 0.


The historical rank and industry rank for Pacira BioSciences's Owner Earnings per Share (TTM) or its related term are showing as below:


During the past 13 years, the highest Price-to-Owner-Earnings ratio of Pacira BioSciences was 124.02. The lowest was 4.84. And the median was 33.75.


PCRX's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 22.94
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

Pacira BioSciences's Earnings per Share (Diluted) for the three months ended in Dec. 2024 was $0.34. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-2.19. It's PE Ratio (TTM) ratio for today is At Loss.

Pacira BioSciences's EPS without NRI for the three months ended in Dec. 2024 was $0.91. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2024 was $1.50. It's PE Ratio without NRI ratio for today is 16.37.


Pacira BioSciences Owner Earnings per Share (TTM) Historical Data

The historical data trend for Pacira BioSciences's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pacira BioSciences Owner Earnings per Share (TTM) Chart

Pacira BioSciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.75 0.91 1.30 0.94 -0.91

Pacira BioSciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.94 2.42 2.42 -0.53 -0.91

Competitive Comparison of Pacira BioSciences's Owner Earnings per Share (TTM)

For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pacira BioSciences's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Pacira BioSciences's Price-to-Owner-Earnings falls into.


;
;

Pacira BioSciences Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Pacira BioSciences's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income -99.6
Depreciation, Depletion and Amortization 78.8
Change In Deferred Tax 20.6
5Y Average of Maintenance Capital Expenditure 23.1
Change In Working Capital -18.5
Shares Outstanding (Diluted Average) 46.2

1. Start with "Net Income" from income statement. Pacira BioSciences's Net Income for the trailing twelve months (TTM) ended in Dec. 2024 was $-99.6 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Pacira BioSciences's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Dec. 2024 was $78.8 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Pacira BioSciences's Change In Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2024 was $20.6 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $23.1 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Pacira BioSciences's 5-Year Average Maintenance Capital Expenditure = $23.1 Mil

5. "Change In Working Capital" is from cashflow statement. Pacira BioSciences's Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2024 was $-18.5 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Pacira BioSciences's Shares Outstanding (Diluted Average) for the months ended in Dec. 2024 was 46.173 Mil.

Pacira BioSciences's Onwer Earnings Per Share for Dec. 2024 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( -99.56 +78.785+20.621
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-23.110270122894+-18.519)/46.173
=-0.91

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=24.56/-0.91
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Pacira BioSciences Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of Pacira BioSciences's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Pacira BioSciences Business Description

Traded in Other Exchanges
Address
5401 West Kennedy Boulevard, Suite 890, Tampa, FL, USA, 33609
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
Executives
Jonathan Slonin officer: Chief Clinical Officer C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Daryl Gaugler officer: Chief Operating Officer C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Marcelo Bigal director C/O PACIRA BIOSCIENCES, INC., 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA FL 33609
Laura Brege director C/O ONYX PHARMACEUTICALS, INC., 2100 POWELL STREET, EMERYVILLE CA 94608
Michael J. Yang director C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Mark Froimson director 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Kristen Marie Williams officer: CAO and General Counsel C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Paul J Hastings director 61 HARTFORD STREET, SAN FRANCISCO CA 94114
Lauren Bullaro Riker officer: Executive Director, Accounting C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, PARSIPPANY NJ 07054
Gary W Pace director C/O RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Alethia Young director C/O GRAPHITE BIO, INC., 201 HASKINS WAY, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Abraham Ceesay director C/O SCPHARMACEUTICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01830
Roy Winston officer: Chief Clinical Officer C/O PACIRA BIOSCIENCES, INC,, 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA FL 33609
Mark A. Kronenfeld director C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 100, PARSIPPANY NJ 07054
Reinhart Charles A. Iii officer: Chief Financial Officer C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054

Pacira BioSciences Headlines

From GuruFocus